Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

virtualization

Overcoming Collaboration Barriers – Perks of Virtual Medical Education

Explore the advantages of virtual collaboration in minimizing production blocking and cognitive interference! Our new video from the "Perks of Virtual Medical Education" series shows how electronic brainstorming can outperform...

Impetus Digital

- PMLiVE

Roche’s subcutaneous Ocrevus granted MHRA approval to treat relapsing and primary MS

The NHS said it expects stock of the ten-minute injection to be available in the coming weeks

- PMLiVE

Online Investigator Meetings: A Customer Story

Discover how Impetus Digital transformed a multicenter Phase III clinical trial with their innovative virtual solutions.

Impetus Digital

Mobile Flexibility – Perks of Virtual Medical Education

Unlock the potential of virtual collaboration with mobile flexibility! Discover how the latest technologies enable you to engage in medical education and collaborate from any corner of the globe. Watch...

Impetus Digital

- PMLiVE

Roche announces CHMP recommendation for PiaSky in rare blood condition PNH

Paroxysmal nocturnal haemoglobinuria affects approximately 20,000 people worldwide

Unrivalled Convenience – Perks of Virtual Medical Education

Explore the unrivalled convenience of virtual collaboration in medical education with our new series, "Perks of Virtual Medical Education." Learn why this flexible, efficient mode of learning is the future...

Impetus Digital

- PMLiVE

Roche’s subcutaneous Ocrevus granted EC approval to treat relapsing and primary MS

The injection has the same twice-yearly schedule as the previously approved intravenous infusion

- PMLiVE

Roche and Ascidian enter neurological disease partnership worth over $1.8bn

More than three billion people worldwide were living with a neurological condition in 2021

- PMLiVE

Roche announces positive phase 3 results for Columvi combination in DLBCL

The most common form of non-Hodgkin lymphoma affects 160,000 people worldwide every year

- PMLiVE

Celltrion’s RoActemra biosimilar shows promise in phase 3 rheumatoid arthritis study

The chronic inflammatory disease affects approximately 1% of the population worldwide

- PMLiVE

Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children

The progressive neuromuscular disease affects approximately one in every 10,000 babies

- PMLiVE

Roche enters licensing agreement with ALZpath to advance Alzheimer’s blood test

The agreement will leverage ALZpath’s pTau217 antibody and Roche’s Elecsys platform

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links